On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Marcus Flather graduated from the Royal Free Hospital School of Medicine and trained in general medicine and cardiology in London and Oxford. In 1988 he joined CTSU at the University of Oxford, working on large clinical trials in acute coronary syndromes, and continued this work at McMaster University from 1993-1996 before being appointed Director of the Clinical Trials and Evaluation Unit and Consultant Cardiologist at Royal Brompton and Harefield Hospitals.
In September 2011 he was appointed Professor of Medicine and Clinical Trials at the University of East Anglia and Director of Research at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich. He is a recognised expert in clinical trials and has more than 20 years’ experience collaborating with academic and industry partners in drug and device development.
In this seminar, Professor Flather will discuss results from the recently published CANTOS trial in which canakinumab therapy yielded benefit for both cardiovascular and cancer outcomes.
